UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1619, 2020

Applied BioSciences Corp.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

000-55523

(Commission File Number)

81-1699502

(IRS Employer Identification No.)

320 Park Ave

New York, New York 10022

(Address of principal executive offices)(Zip Code)

(212) 401-0097

Registrant’s telephone number, including area code

~~9701 Wilshire Blvd., Suite 1000~~ ____________________________________________

Beverly Hills, California 90212

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐¨

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐¨

~~Item~~Forward-looking ~~5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.~~Statements

~~Effective~~Statements ~~March~~in ~~11,~~Exhibit ~~2020,~~99.1 to this Current Report on Form 8-K may be forward-looking and made pursuant to the ~~board~~safe harbor provisions of ~~directors~~the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Applied ~~BioSciences~~Biosciences Corp. (the “Company”) ~~terminated~~or ~~the~~its ~~employment~~management, ofidentify ~~Raymond~~forward-looking ~~Urbanski~~statements. These statements are based on current expectations, estimates and projections about the Company’s ~~Chief~~business ~~Executive~~based, ~~Officer~~in part, ~~effective~~on ~~immediately~~assumptions made by management. ~~Also~~These statements are not guarantees of future performance and involve risks, onuncertainties ~~March~~and 16assumptions that are difficult to predict. Therefore, ~~2020~~actual outcomes and results may, Mrand probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company’s filings with the Securities and Exchange Commission. ~~Urbanski~~Factors ~~resigned~~which could cause actual results to differ materially from these forward-looking statements include such factors as a(i) ~~director~~the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company’s ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, (vii) general industry and market conditions and growth rates, and general economic conditions, and (viii) other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of Form 8-K.

2Item 7.01 Regulation FD Disclosure.

~~SIGNATURES~~On March 19, 2020, the Company issued a press release announcing the retirement of $500,000 of convertible investor debt. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

~~Pursuant~~The toinformation contained in this Item 7.01, and in Exhibit 99.1, referenced herein is being furnished and shall not be deemed “filed” for the ~~requirements~~purposes of Section 18 of the Securities Exchange Act ofor ~~1934,~~incorporated ~~the~~by ~~registrant~~reference ~~has~~in ~~duly~~any ~~caused~~filing ~~this~~under ~~report~~the toSecurities beAct, ~~signed~~unless onthe ~~its~~Company ~~behalf~~expressly byso ~~the~~incorporates ~~undersigned~~such ~~hereunto~~information ~~duly~~by ~~authorized~~reference.

	Applied BioSciences Corp.
Date: March 19, 2020	By:	/s/ Chris Bridges
	Name:	Chris Bridges
	Title:	President

Item 9.01 Financial Statements and Exhibits

3(d) Exhibits:

Exhibit		Description

99.1		Press Release, dated March 19, 2020.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Applied BioSciences Corp.

Date: March 23, 2020	By:	/s/ Chris Bridges
	Name:	Chris Bridges
	Title:	President

Filing Compare · Applied BioSciences Corp.